research papers
Structure of the FP domain of Fbxo7 reveals a novel mode of protein–protein interaction
aChemistry and Biochemistry, Southern Illinois University, 1245 Lincoln Drive, Carbondale, IL 62901, USA, and bComputer Science, Southern Illinois University, 1000 Faner Drive, Carbondale, IL 62901, USA
*Correspondence e-mail: zdu@chem.siu.edu
The FP (Fbxo7/PI31) domains found in the F-box protein Fbxo7 and the proteasome inhibitor PI31 mediate the homodimerization and heterodimerization of Fbxo7 and PI31. Fbxo7 is the substrate-recognition subunit of the SCFFbxo7 (Skp1-Cul1-F-box protein) E3 ubiquitin ligase that catalyzes the ubiquitination of hepatoma up-regulated protein (HURP) and inhibitor of apoptosis protein (IAP). Fbxo7 also interacts with proteins that are not substrates of the ubiquitin proteasome system, such as Cdk6 and PI31. Here, the of the Fbxo7 FP domain is reported at 2.0 Å resolution. The Fbxo7 FP domain adopts an α/β-fold similar to that of the PI31 FP domain. However, an α-helix and three β-strands in the Fbxo7 FP domain are longer than their counterparts in the PI31 FP domain. The differences in these secondary-structural elements are spatially clustered to define a more structured and extended C-terminal end of the Fbxo7 FP domain. The two FP domains also differ substantially in the length and conformation of the longest connecting loop. More importantly, structural differences between the two FP domains lead to drastically different modes of inter-domain protein–protein interaction. The inter-domain interface of the Fbxo7 FP domain is defined by the α-helical surface in one protomer and the β-sheet surface in the other protomer, whereas for the PI31 domain it is defined by either the α-helical surfaces or the β-sheet surfaces in both protomers. The inter-domain interaction of the Fbxo7 FP domain is much more extensive, featuring a larger contact surface area, better shape complementarity and more hydrophobic and hydrogen-bonding interactions. The Fbxo7 FP domain also has the potential to bind two protein partners simultaneously using the α-helical and β-sheet surfaces. The results of this structural study provide critical insights into how Fbxo7 may dimerize (or multimerize) and interact with other regulatory proteins via the FP domain.
Keywords: F-box; Fbxo7; PI31 proteasome inhibitor; Fbxo7/PI31 domain; SCF E3 ubiquitin ligase.
3D view: 4l9c,4l9h
PDB references: FP domain of Fbxo7, 4l9c; 4l9h
1. Introduction
The F-box, which contains approximately 50 amino acids, is a widespread protein motif that mediates protein–protein interactions. The motif was named the F-box owing to its presence in cyclin F, one of the earliest identified F-box proteins (Kumar & Paietta, 1995; Bai et al., 1996). There are a large number of F-box proteins. These proteins often contain some other protein–protein interaction motifs besides the F-box motif. Based on the additional motifs, F-box proteins are classified into several subfamilies: Fbxw for proteins containing WD40 repeats, Fbxl for proteins containing leucine-rich repeats and Fbxo for proteins containing other different or unidentified domains (Cenciarelli et al., 1999; Winston et al., 1999). This nomenclature is used for human and mouse F-box proteins. In other organisms, the presence of an F-box motif is not used as a basis for protein nomenclature.
The best known biological function of F-box proteins is their role as the substrate-recognition component of the ubiquitin proteasome pathway. In this pathway, ubiquitin, a highly conserved 76-amino-acid protein, is conjugated to target proteins via the sequential action of three enzymes (Fig. 1a): the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme and the E3 ubiquitin–protein ligase. Polyubiquitinated proteins are subsequently degraded by the 26S proteasome (Hershko, 2005). The largest and best characterized group of E3 ligases is the SCF (Skp1, cullin 1, F-box protein) family. The multicomponent SCF complexes consist of three common components, Skp1 (S-phase kinase-associated protein 1), cullin 1 and Rbx1 (RING-box protein 1), as well as an F-box protein as the variable component. Structural and biochemical studies of SCF complexes reveal that cullin 1 serves as a rigid scaffold to position the Skp1 and Rbx1 subunits. In turn, Skp1 binds the F-box protein subunit by interacting with the F-box motif, while Rbx1 binds a ubiquitin-charged E2 enzyme. The F-box protein binds specific substrates and recruits the substrates to the SCF complex (Schulman et al., 2000; Zheng et al., 2002; Wu et al., 2003; Goldenberg et al., 2004; Hao et al., 2007; Mizushima et al., 2007; Zeng et al., 2010). Numerous SCF-type E3 ligases exist. Each can only recognize a subset of protein substrates. The large number of diverse F-box proteins provides recognition specificities for various substrates. F-box proteins in each of the three subfamilies (Fbxw, Fbxl and Fbxo) have been shown to function in the SCF complexes (Cenciarelli et al., 1999).
F-box-only protein 7 (Fbxo7) is a member of the Fbxo subfamily of F-box proteins (Hsu et al., 2004; Laman et al., 2005). In humans, two protein isoforms have been identified, with isoform 1 (more abundant) and isoform 2 containing 522 and 443 amino acids, respectively (Zhao et al., 2011). Isoform 2 lacks the N-terminal 91 amino acids of isoform 1, replacing them with a different 12-amino-acid N-terminal sequence. Here, the term Fbxo7 refers to isoform 1 unless indicated otherwise.
As shown in Fig. 1(b), Fbxo7 contains a ubiquitin-like domain (Ubl; amino acids 1–78), a Cdk6-interacting motif (cdk; amino acids 129–169), an Fbxo7/PI31 domain (FP; amino acids 180–324), an F-box motif (amino acids 332–375) and a proline-rich region (PRR; amino acids 423–522) (Kirk et al., 2008). Sequence homology between the Ubl domain and ubiquitin (20% identity and 38% similarity) suggests that the Ubl domain might interact with the ubiquitin-binding domains (UBDs) of ubiquitin-receptor proteins, including those in the proteasome. The cdk motif binds CDK6. The FP domain was first identified on the basis of its sequence homology to the N-terminal domain of the proteasome inhibitor PI31. It has been shown that the FP domains of Fbxo7 and PI31 mediate homodimerization and heterodimerization of the proteins. The F-box motif is required for interaction with Skp1. The sequence between the F-box motif and PRR also contributes to Skp1 binding, suggesting that the F-box motif of Fbxo7 might have a broader boundary (Hsu et al., 2004). The PRR is most likely to be unstructured. It mediates the specific binding of protein substrates of the SCFFbxo7 ligases (Hsu et al., 2004; Chang et al., 2006).
Fbxo7 is one of the Fbxo subfamily proteins that have been shown to form functional SCF complexes. Specific protein substrates of the SCFFbxo7 ligase complex include HURP (hepatoma up-regulated protein), cIAP1 (cellular inhibitor of apoptosis protein 1) and TRAF2 (TNF receptor-associated factor 2) (Kuiken et al., 2012). Fbxo7 also interacts with other proteins that are not substrates for ubiquitin-mediated degradation, including Cdk6, PI31 and p27 (Laman et al., 2005; Kirk et al., 2008). Selective binding of Fbxo7 to Cdk6 enhances the assembly and activity of the cyclin D–Cdk6 complex, which is responsible for the ability of Fbxo7 to transform murine fibroblasts that are tumourigenic in athymic nude mice.
The et al., 2008). The FP domain adopts a novel α/β-fold with five α-helices and five β-strands. The five β-strands form an antiparallel β-sheet located on one side of the domain. The other side of the domain is mainly defined by the α-helices. Inter-domain protein–protein contacts in the crystal are mediated by two different molecular interfaces: the α-helical interface and the β-sheet interface. It was proposed that the α-helical interface mediates homodimerization of the FP domain of PI31 and the β-sheet interface mediates heterodimerization of the FP domains of PI31 and Fbxo7.
of the FP domain of PI31 has been determined (KirkThe precise physiological role of the Fbxo7–PI31 interaction is not known. However, studies of homologous proteins in Drosophila suggest that Fbxo7 and PI31 may form a conserved regulatory complex that stimulates proteasome activity (Bader et al., 2011). The Drosophila F-box protein Nutcracker shares some degree of homology with Fbxo7. Nutcracker also contains an FP domain that is located N-terminal to the F-box motif. It has been shown that Nutcracker interacts with DmPI31, the Drosophila homologue of human PI31, through heterodimerization of their FP domains (Bader et al., 2011). Nutcracker–DmPI31 interaction stabilized DmPI31. The two proteins function together as a complex to stimulate proteasome activity, which is required for non-apoptotic caspase activation and sperm differentiation in Drosophila.
Fbxo7 has been implicated in cancers and neurodegenerative diseases. It has been shown that Fbxo7 is overexpressed in tumours of the lung and colon (Laman et al., 2005). It is also well known that mutations in the Fbxo7 gene (FBXO7) cause PARK15, an early-onset Parkinsonian disease (Shojaee et al., 2008; Di Fonzo et al., 2009).
In spite of the biological and physiological importance of Fbxo7, no structural studies of this protein have been reported. In this paper, we present the α/β protein fold as the FP domain of PI31. However, the FP domain of Fbxo7 utilizes an α-helical–β-sheet interface to mediate inter-domain protein–protein interactions. This interface is drastically different from and much more extensive than the α-helical or β-sheet interfaces observed in the structure of the FP domain of PI31. Moreover, the FP domain of Fbxo7 has the potential to simultaneously interact with two protein partners via different molecular surfaces. Our structural study provides critical insights into how Fbxo7 may dimerize (or multimerize) and interact with other regulatory proteins via the FP domain.
of the FP domain of Fbxo7. Our results show that the FP domain of Fbxo7 shares the same2. Materials and methods
2.1. Cloning
A cDNA clone for full-length Fbxo7 isoform 1 (GenBank BC008361) was purchased from the DNASU Plasmid Repository. The DNA encoding the FP domain and an extra C-terminal sequence (residues 181–335) was amplified by PCR from the plasmid. The DNA was inserted into an in-house-modified ligation-independent cloning (LIC) vector that contains DNA sequences encoding the HaloTag (Los et al., 2008), a His tag and an eight-amino-acid recognition sequence for HRV (Human rhinovirus) 3C protease followed by a specific LIC sequence. Protein expression was carried out using NiCo21 (DE3) Escherichia coli cells (New England Biolabs).
2.2. Protein expression, purification and crystallization
The FP domain of Fbxo7 was expressed in E. coli as a fusion protein with an N-terminal HaloTag and His tag. Protein expression was induced using a 0.4 mM final concentration of IPTG when the cell culture reached an OD600 of 0.6–0.8. After induction, the temperature was lowered to 288 K and the culture was allowed to grow overnight. Expressed proteins were purified using NTA affinity resin. The fusion tags were then cleaved by HRV 3C protease. The cleaved tags were separated from the target protein by a reverse IMAC process. The purified proteins were concentrated to a concentration of ∼10 mg ml−1 in a buffer consisting of 25 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT.
To obtain SeMet-labelled protein, the cells were grown in M9 minimal culture until an OD600 of 0.6–0.8 was reached. Six amino acids (leucine, isoleucine, lysine, phenylalanine, threonine and valine) were added to the culture at final concentrations of 50–100 mg l−1 to inhibit the methionine-biosynthesis pathway. After 30 min of continuous incubation, L-selenomethionine was added to a final concentration of 50 mg l−1. Protein expression was induced using a 0.4 mM final concentration of IPTG at 288 K overnight.
Crystals of the protein construct were obtained at 295 K by sitting-drop vapour diffusion against 50 µl well solution using 96-well format crystallization plates. Two crystal forms were obtained. Crystals belonging to P43212 were obtained with a well solution consisting of 20% PEG 3350, 50 mM MOPS buffer pH 7.0, 100 mM KBr, 10%(v/v) glycerol. Crystals belonging to P212121 were obtained with a well solution consisting of 20% PEG 3350, 50 mM bis-tris buffer pH 7.2, 100 mM KBr, 10%(v/v) glycerol. Crystals were flash-cooled in liquid nitrogen.
2.3. Data collection, data processing and structure determination
Data collection was carried out on beamlines 21-ID-D, 21-ID-F and 21-ID-G of LS-CAT at the Advanced Photon Source (Argonne National Laboratory). Data were processed, integrated and scaled with the programs MOSFLM and SCALA in CCP4 (Battye et al., 2011; Winn et al., 2011). The structure in P43212 was solved by SAD using a data set collected at the peak wavelength of Se (0.97872 Å) from a single crystal of SeMet-labelled protein. The PHENIX package (Adams et al., 2011) was used to locate the Se atoms and to build the initial structure. Interactive model building was carried out with Coot (Emsley et al., 2010). The structure was refined using PHENIX. The structure in P212121 was solved by using Phaser (Storoni et al., 2004) as implemented in the PHENIX package. The structure in P43212 was used as the search model for All plausible space groups of the P222 family were tried. A single solution was found in P212121. Structure was carried out by PHENIX. In PHENIX the initial isotropic B factors were all set to 20 Å2 and individual B factors were refined. No restraints were used in the except that weightings between X-ray and stereochemistry/ADP terms were optimized using the default values. No H atoms were included in the The input coordinates for did not contain water molecules. Water molecules were automatically updated during the process. The was carried out in real space using simulated annealing (Cartesian, from 5000 to 300 K). The structure-determination statistics are given in Table 1. The figures were prepared with PyMOL (The PyMOL Molecular Graphics System v.1.5.0.4; Schrödinger). The structure in P43212 was used to generate all of the figures.
|
Atomic coordinates and diffraction data for the structures in space groups P43212 and P212121 have been deposited in the Protein Data Bank with accession codes 4l9h and 4l9c , respectively.
3. Results
3.1. Overall structure
The FP domain of Fbxo7 was predicted to include residues 180–324 of the protein (Kirk et al., 2008). In our study, the FP domain construct contains residues 181–335, including an extra C-terminal sequence of 11 amino acids outside the putative FP domain boundary. The protein construct also contains an artificial sequence GPSSP at the N-terminus as a cloning artefact.
The protein construct crystallizes in two different crystal forms in space groups P43212 and P212121. The structure in P43212 was solved by the SAD phasing method using a data set collected from a single crystal of SeMet-labelled protein. The structure in P212121 was solved by the molecular-replacement method (Table 1).
In both structures, electron density was observed for residues 181–330. Electron density was also observed for the N-terminal artificial sequence in the structure in P43212. No electron density was observed for residues 331–335 in both structures. The two structures are very similar (pairwise r.m.s.d. of 0.340 Å). The structures in space groups P43212 and P212121 contained two molecules and one molecule in the respectively. Despite this difference, the inter-domain protein–protein interactions in both structures were virtually identical. In the following sections, we will mainly discuss the structure in P43212.
The FP domain of Fbxo7 adopts an α/β-fold that is similar to the FP domain of PI31 (Figs. 1c and 1e). Both FP domains contain five α-helices and five β-strands. The five β-strands form an antiparallel β-sheet located on one side of the molecule. The five α-helices pack against the β-sheet on the other side (Fig. 1d). Most of the connecting loops are short. Two relatively long connecting loops are present between α-helices α3 and α4 (referred to as the α3–α4 loop; nine amino acids) and β-strands β1 and β2 (referred to as the β1–β2 loop; 17 amino acids). These loops seem to be well structured. All of the residues within the loops yield good electron density. Comparing the structures in the two different space groups, the longer β1–β2 loop has basically the same conformation, while the α3–α4 loop shows a slight difference, most likely owing to different crystal packing.
Most of the secondary-structural elements are comparable in the two structures. However, helix α5 and strands β3, β4 and β5 are longer in the FP domain of Fbxo7 (Fig. 1c). The differences in these secondary-structural elements are spatially clustered to define a more extended and structured C-terminal end of the FP domain of Fbxo7 (Fig. 1e). Most noticeably, the FP domain of Fbxo7 features a long helix α5 with seven helical turns and a pronounced kink in the middle. Helix α5 in the FP domain of PI31 is only about half as long (comparable to α5a in the FP domain of Fbxo7). The crystallization construct of the PI31 FP domain contains more C-terminal residues that correspond to residues within helix α5b of the Fbxo7 FP domain (Fig. 1c). However, no electron density was observed for the C-terminal residues in the PI31 FP domain, indicating that these residues are flexible in the structure. The two FP domains also show significant differences in the length and conformation of the β1–β2 loop (Figs. 1c and 1e).
In short, although the FP domains of Fbxo7 and PI31 share the same protein fold, they show significant differences in many of the structural elements. These differences define very different molecular surfaces of the two FP domains that mediate different modes of protein–protein interaction (see below for details).
3.2. Intramolecular interactions of the Fbxo7 FP domain
The FP domain of Fbxo7 features a hydrophobic core that is centred around helix α2 (Fig. 2a). Most of the residues of helix α2 have a hydrophobic side chain, including a stretch of 11 amino acids (198ALIVLIHLLML) in the middle of the helix (Fig. 1b). Helix α2 is therefore mostly hydrophobic on all sides. A large number of residues from other structural elements pack around helix α2 to form the hydrophobic core of the Fbxo7 FP domain. Most of these residues have a hydrophobic side chain, including Leu183, Leu186, Ala190, Cys192, Leu199, Ile200, Val201, Leu202, Ile203, His204, Leu205, Leu206, Met207, Leu208, Pro214, Met224, Pro225, Trp228, Leu236, His240, Ala248, Leu250, Cys252, Pro254, Ile259, Val261, Ala263, Leu265, Ile267, Val274, Leu277, Leu279, Phe284, Ile285, Ile297, Ile304, Phe308, Leu312, Val313, Leu316 and Leu317 (Fig. 2a, green sticks). The hydrophobic moieties of the side chains of Tyr212, Lys229, Tyr234, Tyr238 and Tyr298 (Fig. 2a, yellow sticks) also participate in the formation of the hydrophobic core.
Besides the extensive hydrophobic interactions, other kinds of molecular interactions such as hydrogen-bonding interactions also contribute to the folding of the Fbxo7 FP domain. Most noticeably, hydrogen-bonding interactions play an important role in maintaining the conformation of the β1–β2 loop (Fig. 2b). A total of 22 hydrogen bonds mediate medium-range or long-range interactions within the loop or between the loop and neighbouring structural elements. Electron densities for four structured water molecules involved in the hydrogen-bonding network are also clearly observed.
Owing to the presence of extensive intramolecular interactions, the Fbxo7 FP domain has a tightly packed stable structure.
3.3. Intermolecular interactions of the Fbxo7 FP domain
For the crystal in P212121, there are two FP domains in the which contact each other through substantial inter-domain protein–protein interactions. The of the crystal in P43212 contains only one FP domain. However, two FP domains from adjacent asymmetric units show very similar inter-domain protein–protein interactions (Fig. 3).
It should be noted that the crystallization protein construct contains an extra C-terminal sequence (amino acids 325–335) that should not be part of the FP domain (Fig. 1b). This sequence makes a reverse turn at the end of helix α5 and runs antiparallel to the helix. No electron density was observed in the protein-interaction interface. The C-terminal end of the sequence points inwards, where there is no space to accommodate more residue(s). In view of this, the peculiar positioning of residues 325–330 is most likely to be driven by crystal packing. We therefore exclude these residues in the following analysis of the intermolecular interactions of the Fbxo7 FP domain.
The inter-domain protein–protein interaction interface of the Fbxo7 FP domain is best described as an αβ interface because the contact surfaces in the two interacting FP domains are mainly defined by α-helices in one protomer and β-strands in the other protomer. Fig. 2(a) provides a good view of the α-helical interacting surface that is constituted by the N-terminal end of α1, the C-terminal end of α2, most of α5 and portions of the β1–β2 and β2–β3 connecting loops. The β-sheet interacting surface is defined by the four β-strands β2–β5, as shown by the molecular surface facing left in Fig. 2(b). Interaction between two FP domains through the αβ interface buries 1700 Å2 of solvent-accessible molecular surface area from the two domains (1934 Å2 if the C-terminal sequence of amino acids 325–330 is included in the calculation). The buried surface area is significantly larger than the estimated minimal area of 1200 Å2 required for a stable protein–protein complex (Chothia & Janin, 1975; Jones & Thornton, 1995).
The inter-domain protein–protein interaction is mediated by several driving forces including shape complementarity and hydrogen-bonding and hydrophobic interactions. As shown in Figs. 3(a) and 3(c), the overall shapes of the α-helical and β-sheet molecular surfaces of the Fbxo7 FP domain have a high degree of complementarity. In the αβ interface, 23 inter-domain hydrogen bonds (some of which involve structured water molecules) are present (Fig. 3b). Inter-domain hydrophobic interactions are mediated by two hydrophobic patches on the surface of the FP domain. On the α-helical surface, the hydrophobic patch is defined by the side chains of His181 (noncharged and hydrophobic at neutral pH), Leu208, Ile213, Pro214, Ala219, Lys220 (the aliphatic moiety), Ala221, Leu222, His240, Pro241 and Leu242 (Fig. 3d; the side chains are represented as cyan sticks with black residue names). On the β-sheet surface, the hydrophobic patch is defined by the side chains of Leu230, Val233, Val253, Pro254, Leu255, Gly256, Leu258, Val260, Leu280, Phe284 and Leu307 (Fig. 3d; the surface areas defined by these residues are indicated by italic residue names in red). Some of the hydrophobic interactions are augmented by shape complementarity, as shown in Fig. 3(c) for the side chains of Val253 and Leu255, for example (note that the shown electron-density meshes are smaller than the van der Waals radius).
In a previous study (Kirk et al., 2008), it was shown that a V253E mutation in an Fbxo7 protein construct (amino acids 169–398) disrupted the homodimerization of Fbxo7 and the heterodimerization between Fbxo7 and PI31. Similarly, mutation of this conserved valine in Nutcracker (Val to Glu) significantly weakens the Nutcracker–DmPI31 interaction in Drosophila (Bader et al., 2011). As shown in Figs. 3(c) and 3(d), Val253 is located at the centre of the hydrophobic patch of the β-sheet surface. This central location explains the effect of the V253E mutation.
The presence of extensive molecular interactions and shape complementarity at the αβ interface of the Fbxo7 FP domain indicates that the interface mediates stable and most likely genuine protein–protein interaction. In solution, the protein construct used in this study exists as a dimer, based on results from (Supplementary Fig. S11). In a previous study (Kirk et al., 2008), it was shown that an Fbxo7 protein construct (amino acids 169–389) containing the FP domain homodimerized. In the crystals in both space groups P212121 and P43212 each FP domain interacts with two adjacent FP domains using the α-helical and β-sheet interacting surfaces located on opposite sides of the domain. The same αβ interface is present at both of the inter-domain interacting sites (Fig. 4a).
3.4. Different modes of protein–protein interaction of the two FP domains
The crystal structures of the FP domains of Fbxo7 (this study) and PI31 (Kirk et al., 2008) reveal drastically different modes of inter-domain protein–protein interaction (Figs. 4a and 4b). In the structure of the PI31 FP domain, two FP domains interact with each other through either the `α interface' or the `β interface' mediated by the α-helical or β-sheet surfaces of the FP domains, respectively (Fig. 4b). Each of these two interfaces is formed by the self-association of the same molecular surface in the two adjacent FP domains (either the α-helical surfaces of the two domains in red and green or the β-sheet surfaces of the two domains in green and blue in Fig. 4b). Inter-domain protein–protein interaction through the α interface buries 1114 Å2 of solvent-accessible molecular surface area from the two domains. For the β interface, 560 Å2 of surface area is buried. Obviously, the molecular surfaces involved in the inter-domain protein–protein interactions in the structure of the PI31 FP domain are much smaller than those in the structure of the Fbxo7 FP domain.
More detailed comparisons in terms of the specific features that are present at the inter-domain interfaces are even more revealing. Probably owing to the self-associating nature of the α and β interfaces of the PI31 FP domain, the degree of shape complementarity at these interfaces is low (Fig. 4b). The number of inter-domain hydrogen bonds at the α and β interfaces (eight and two, respectively) of the PI31 FP domain is much smaller than the number (23) at the αβ interface of the Fbxo7 FP domain. Corresponding to the smaller molecular surface areas involved in inter-domain interaction, hydrophobic contacts at the α and β interfaces of the PI31 FP domain are also less extensive than at the αβ interface of the Fbxo7 FP domain.
4. Discussion
The results of our studies confirm the structural relationship between Fbxo7 and PI31: both proteins contain an FP domain with a similar overall fold. However, significant structural differences are observed between the two FP domains, especially regarding the modes of inter-domain protein–protein interaction. It should be noted that there is a difference in the length of the crystallization protein constructs used in the two structural studies. The protein construct for the crystallization of the Fbxo7 FP domain contains an extra C-terminal sequence that extends into the F-box motif (Fig. 1c). It is possible that the presence of this extra sequence stabilizes the structure of helix α5b in the Fbxo7 FP domain. Formation of helix α5b in turn stabilizes the β-strands (β3, β4 and β5) that are in close proximity to helix α5b (Fig. 1d). The sequences of the two FP domains are 22.5% identical and 41.7% homologous (Fig. 1c). With this degree of sequence homology, it is also possible that the observed structural differences between the two FP domains are genuine and the structural differences may reflect functional differences
Fbxo7 and PI31 have different biological functions and domain structures (Fig. 1b). The FP domain of PI31 is located at the N-terminus (amino acids 1–150) and is followed by an unstructured proline-rich region (amino acids 151–271). In Fbxo7, the FP domain is closely juxtaposed to the most likely well structured F-box motif, suggesting that they may act together in certain function(s) of Fbxo7. This possibility is supported by the observation that the FP domain and F-box motif of Nutcracker are both required for positive regulation of DmPI31 stability (Bader et al., 2011). In view of the different contexts of the FP domains of Fbxo7 and PI31, it is fully possible that the two FP domains may have some genuine structural differences.
The homodimerization of Fbxo7 and the heterodimerization of Fbxo7 and PI31 may be functionally important. Quite a number of F-box proteins are known to mediate dimerization of their corresponding SCF E3 ubiquitin ligases. These include proteins from all three F-box protein subfamilies, such as Fbw7, Cdc4, β-TrCP, Met30 and Pop1/Pop2 from the Fbxw subfamily, Skp2 from the Fbxl subfamily and Fbx4 from the Fbxo subfamily (Hao et al., 2007; Welcker & Clurman, 2007; Tang et al., 2007; Li & Hao, 2010). Dimerization of SCF ligases through their F-box protein subunits is emerging as an important feature for the ubiquitination activities of the ligases (Petroski & Deshaies, 2005). It is therefore key to understand the molecular basis of F-box protein association.
Homodimerization of F-box proteins of the Fbxw subfamily is mediated by a small (∼45 amino acids) and highly conserved motif known as the D domain. Similar to the FP domain of Fbxo7, the D domain is closely juxtaposed to the F-box motif in Fbxw proteins. Structures of the D domains of Cdc4 and β-TrCP have been determined (Tang et al., 2007). Each of the D domains contains three α-helices that fold into similar overall structures. The D domains self-associate in a side-by-side manner to form a right-handed superhelical parallel dimer (Fig. 5a). The molecular details of the homodimerization of Fbx4 are revealed by the of an Fbx4 core fragment (containing the F-box motif and the C-terminal substrate-binding G domain) in complex with Skp1 (Li & Hao, 2010). The Fbx4core–Skp1 complexes form an antiparallel homodimer mediated by Fbx4. Dimerization is achieved by interaction between a loop (within the linker region connecting the F-box motif and G domain) and the G domain (Fig. 5b). Apparently, the possible mode of FP domain-mediated dimerization of Fbxo7 as revealed in this study is different from those of other F-box proteins. More interestingly, as shown in Fig. 4(a), the FP domain of Fbxo7 has the potential to mediate the simultaneous binding of two protein partners using different molecular surfaces. This unique potential may enable the FP domain to serve as a versatile protein–protein interaction module that plays important roles in various functions of Fbxo7.
It is not known whether the functional SCFFbxo7 complex is monomeric, dimeric or multimeric. The ability of the FP domain of Fbxo7 to dimerize (or multimerize as shown in Fig. 4a) suggests that the SCFFbxo7 complex may function as a dimer or a multimer. Fbxo7 is somewhat special in the F-box protein family because several of the partners of Fbxo7 (such as Cdk6, PI31 and p27) are not substrates of the ubiquitin proteasome system, indicating that Fbxo7 may participate in both SCF-dependent and SCF-independent activities. How Fbxo7 balances these activities is a central issue for understanding the functional mechanisms of Fbxo7. Because Fbxo7 and PI31 both contain an FP domain that has the ability to homodimerize and heterodimerize, it is possible that PI31 may antagonize the homodimerization of Fbxo7 and therefore modulate the function of the SCFFbxo7 ligase complex. However, since the Fbxo7 FP domain has the potential to simultaneously interact with two binding partners (Fig. 4a), the formation of an FPPI31–FPFbxo7–FPFbxo7 trimeric complex (or a multimeric complex containing the two FP domains) is also possible. In the latter scenario, binding of PI31 to Fbxo7 via their FP domains may not disrupt the functional dimeric (or multimeric) SCFFbxo7 complex. It is known that some E3 ubiquitin ligases physically associate with the 26S proteasome. The substrate-bound E3 ubiquitin ligase may participate in the delivery of substrates to the proteasome (Xie & Varshavsky, 2000; Bloom et al., 2006; Farrás et al., 2001). PI31 is an established regulatory protein that controls proteasome activities (Zaiss et al., 2002; McCutchen-Maloney et al., 2000; Zaiss et al., 1999; Bader et al., 2011). Interaction of Fbxo7 and PI31 may play a functional role in bringing the SCFFbxo7 ligase complex to the proteasome.
Supporting information
3D view: 4l9c,4l9h
PDB references: FP domain of Fbxo7, 4l9c; 4l9h
Supporting information file. DOI: 10.1107/S1399004713025820/dw5066sup1.pdf
References
Adams, P. D. et al. (2011). Methods, 55, 94–106. Web of Science CrossRef CAS PubMed Google Scholar
Bader, M., Benjamin, S., Wapinski, O. L., Smith, D. M., Goldberg, A. L. & Steller, H. (2011). Cell, 145, 371–382. Web of Science CrossRef CAS PubMed Google Scholar
Bai, C., Sen, P., Hofmann, K., Ma, L., Goebl, M., Harper, J. W. & Elledge, S. J. (1996). Cell, 86, 263–274. CrossRef CAS PubMed Web of Science Google Scholar
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. W. (2011). Acta Cryst. D67, 271–281. Web of Science CrossRef CAS IUCr Journals Google Scholar
Bloom, J., Peschiaroli, A., DeMartino, G. & Pagano, M. (2006). Cell Div. 1, 5. Web of Science CrossRef PubMed Google Scholar
Cenciarelli, C., Chiaur, D. S., Guardavaccaro, D., Parks, W., Vidal, M. & Pagano, M. (1999). Curr. Biol. 9, 1177–1179. Web of Science CrossRef PubMed CAS Google Scholar
Chang, Y.-F., Cheng, C.-M., Chang, L.-K., Jong, Y.-J. & Yuo, C.-Y. (2006). Biochem. Biophys. Res. Commun. 342, 1022–1026. Web of Science CrossRef PubMed CAS Google Scholar
Chothia, C. & Janin, J. (1975). Nature (London), 256, 705–708. CrossRef PubMed CAS Web of Science Google Scholar
Di Fonzo, A. et al. (2009). Neurology, 72, 240–245. Web of Science PubMed CAS Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Farrás, R., Ferrando, A., Jásik, J., Kleinow, T., Okrész, L., Tiburcio, A., Salchert, K., del Pozo, C., Schell, J. & Koncz, C. (2001). EMBO J. 20, 2742–2756. Web of Science PubMed Google Scholar
Goldenberg, S. J., Cascio, T. C., Shumway, S. D., Garbutt, K. C., Liu, J., Xiong, Y. & Zheng, N. (2004). Cell, 119, 517–528. Web of Science CrossRef PubMed CAS Google Scholar
Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W. & Pavletich, N. P. (2007). Mol. Cell, 26, 131–143. Web of Science CrossRef PubMed CAS Google Scholar
Hershko, A. (2005). Cell Death Differ. 12, 1191–1197. Web of Science CrossRef PubMed CAS Google Scholar
Hsu, J.-M., Lee, Y.-C. G., Yu, C.-T. R. & Huang, C.-Y. F. (2004). J. Biol. Chem. 279, 32592–32602. Web of Science CrossRef PubMed CAS Google Scholar
Jones, S. & Thornton, J. M. (1995). Prog. Biophys. Mol. Biol. 63, 31–65. CrossRef CAS PubMed Web of Science Google Scholar
Kirk, R., Laman, H., Knowles, P. P., Murray-Rust, J., Lomonosov, M., Meziane, el K. & McDonald, N. Q. (2008). J. Biol. Chem. 283, 22325–22335. Web of Science CrossRef PubMed CAS Google Scholar
Kuiken, H. J., Egan, D. A., Laman, H., Bernards, R., Beijersbergen, R. L. & Dirac, A. M. (2012). J. Cell. Mol. Med. 16, 2140–2149. Web of Science CrossRef CAS PubMed Google Scholar
Kumar, A. & Paietta, J. V. (1995). Proc. Natl Acad. Sci. USA, 92, 3343–3347. CrossRef CAS PubMed Web of Science Google Scholar
Laman, H., Funes, J. M., Ye, H., Henderson, S., Galinanes-Garcia, L., Hara, E., Knowles, P., McDonald, N. & Boshoff, C. (2005). EMBO J. 24, 3104–3116. Web of Science CrossRef PubMed CAS Google Scholar
Li, Y. & Hao, B. (2010). J. Biol. Chem. 285, 13896–13906. Web of Science CrossRef CAS PubMed Google Scholar
Los, G. V. et al. (2008). ACS Chem. Biol. 3, 373–382. Web of Science CrossRef PubMed CAS Google Scholar
McCutchen-Maloney, S. L., Matsuda, K., Shimbara, N., Binns, D. D., Tanaka, K., Slaughter, C. A. & DeMartino, G. N. (2000). J. Biol. Chem. 275, 18557–18565. Web of Science PubMed CAS Google Scholar
Mizushima, T., Yoshida, Y., Kumanomidou, T., Hasegawa, Y., Suzuki, A., Yamane, T. & Tanaka, K. (2007). Proc. Natl Acad. Sci. USA, 104, 5777–5781. Web of Science CrossRef PubMed CAS Google Scholar
Petroski, M. D. & Deshaies, R. J. (2005). Nature Rev. Mol. Cell Biol. 6, 9–20. Web of Science CrossRef CAS Google Scholar
Schulman, B. A., Carrano, A. C., Jeffrey, P. D., Bowen, Z., Kinnucan, E. R., Finnin, M. S., Elledge, S. J., Harper, J. W., Pagano, M. & Pavletich, N. P. (2000). Nature (London), 408, 381–386. Web of Science PubMed CAS Google Scholar
Shojaee, S., Sina, F., Banihosseini, S. S., Kazemi, M. H., Kalhor, R., Shahidi, G. A., Fakhrai-Rad, H., Ronaghi, M. & Elahi, E. (2008). Am. J. Hum. Genet. 82, 1375–1384. Web of Science CrossRef PubMed CAS Google Scholar
Storoni, L. C., McCoy, A. J. & Read, R. J. (2004). Acta Cryst. D60, 432–438. Web of Science CrossRef CAS IUCr Journals Google Scholar
Tang, X., Orlicky, S., Lin, Z., Willems, A., Neculai, D., Ceccarelli, D., Mercurio, F., Shilton, B. H., Sicheri, F. & Tyers, M. (2007). Cell, 129, 1165–1176. Web of Science CrossRef PubMed CAS Google Scholar
Welcker, M. & Clurman, B. E. (2007). Cell Div. 2, 7. Web of Science CrossRef PubMed Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Winston, J. T., Koepp, D. M., Zhu, C., Elledge, S. J. & Harper, J. W. (1999). Curr. Biol. 9, 1180–1182. Web of Science CrossRef PubMed CAS Google Scholar
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W. & Pavletich, N. P. (2003). Mol. Cell, 11, 1445–1456. Web of Science CrossRef PubMed CAS Google Scholar
Xie, Y. & Varshavsky, A. (2000). Proc. Natl Acad. Sci. USA, 97, 2497–2502. Web of Science CrossRef PubMed CAS Google Scholar
Zaiss, D. M. W., Standera, S., Holzhütter, H., Kloetzel, P.-M. & Sijts, A. J. A. M. (1999). FEBS Lett. 457, 333–338. Web of Science CrossRef PubMed CAS Google Scholar
Zaiss, D. M. W., Standera, S., Kloetzel, P.-M. & Sijts, A. J. A. M. (2002). Proc. Natl Acad. Sci. USA, 99, 14344–14349. Web of Science CrossRef PubMed CAS Google Scholar
Zeng, Z., Wang, W., Yang, Y., Chen, Y., Yang, X., Diehl, J. A., Liu, X. & Lei, M. (2010). Dev. Cell, 18, 214–225. Web of Science CrossRef CAS PubMed Google Scholar
Zhao, T., De Graaff, E., Breedveld, G. J., Loda, A., Severijnen, L. A., Wouters, C. H., Verheijen, F. W., Dekker, M. C. J., Montagna, P., Willemsen, R., Oostra, B. A. & Bonifati, V. (2011). PLoS One, 6, e16983. Web of Science CrossRef PubMed Google Scholar
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., Conaway, R. C., Conaway, J. W., Harper, J. W. & Pavletich, N. P. (2002). Nature (London), 416, 703–709. Web of Science CrossRef PubMed CAS Google Scholar
© International Union of Crystallography. Prior permission is not required to reproduce short quotations, tables and figures from this article, provided the original authors and source are cited. For more information, click here.